[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 194
Citations 0
Correspondence
May 2013

Older vs Newer Antiepileptic Drugs: Is Old Still Gold?—Reply

Author Affiliations

Author Affiliations: Department of Neurology, Royal Melbourne Hospital and Department of Medicine, University of Melbourne, Victoria, Australia.

JAMA Neurol. 2013;70(5):656-657. doi:10.1001/jamaneurol.2013.214

In reply

We thank Sethi for his interest in our article reporting the results of the KONQUEST (Keppra vs Older AEDs evaluating Neuropsychiatric, Neurocognitive and QUality of life outcomes in treatment of Epilepsy as Substitution monoTherapy) study.1 We acknowledge that drug absorption may vary between brand name antiepileptic drugs (AEDs) and their generic counterparts. In the KONQUEST study, all patients were randomized to treatment with brand name AEDs (ie, Keppra [levetiracetam], Tegretol CR [controlled-release carbamazepine], or Epilim [enteric-coated valproate]), so this should not have been a factor influencing the results of this study. We agree that the study findings raise doubts about whether newer AEDs, which are more expensive, result in overall better outcomes for patients than older generation AEDs.

First Page Preview View Large
First page PDF preview
First page PDF preview
×